ADMA Biologics, Inc. (ADMA)
ADMA Biologics, Inc.
465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552
https://www.admabiologics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 624
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Adam S. Grossman | Co-Founder, President, CEO, Interim CFO & Director | 1.59M | N/D | 1977 |
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder & Vice Chairman of the Board | 90k | N/D | 1948 |
| Ms. Kaitlin Kestenberg | COO & Senior VP of Compliance | N/D | N/D | 1987 |
| Mr. Drew Pantello | Vice President of Marketing & Corporate Development | N/D | N/D | N/D |
| Ms. Cindy Petersen | Executive Director of Human Resources | N/D | N/D | N/D |
| Mr. Skyler Bloom | Senior Director of Business Development & Corporate Strategy | N/D | N/D | N/D |
Descripción
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de ADMA Biologics, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 7; Derechos del accionista: 8; Compensación: 7.
